Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Attovia Therapeutics, Inc. (ATTO : NSDQ)

• Company Description    Attovia Therapeutics Inc. is a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need. The company's lead programs include ATTO-1310, ATTO-2306 and ATTO-1091. Attovia Therapeutics Inc. is based in SAN CARLOS, Calif. Number of Employees: 44

• Price / Volume Information    Yesterday's Closing Price: $25.55 Daily Weekly Monthly 20 Day Moving Average: 236,459 shares Shares Outstanding: 45.65 (millions) Market Capitalization: $1,166.39 (millions) Beta: 52 Week High: $28.00 52 Week Low: $16.15 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 28.78% 29.36% 12 Week % % Year To Date % %

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1091 INDUSTRIAL ROAD - SAN CARLOS,CA 94070 USA ph: 510-399-5001 fax: - ir@attovia.com http://www.attovia.com

• General Corporate Information    Officers Tao Fu - Chief Executive Officer; President James Topper - Chairman Steven Chan - Chief Financial Officer Zaneta Odrowaz - Treasurer; Secretary Mitchell Gold - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 04987L102 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 12/02/26 Share - Related Items Shares Outstanding: 45.65 Most Recent Split Date: (:1) Beta: Market Capitalization: $1,166.39 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.74 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-4.06 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 12/02/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/26 - - 03/31/26 - - 12/31/25 - - ROA 06/30/26 - - 03/31/26 - - 12/31/25 - - Current Ratio 06/30/26 - - 03/31/26 - - 12/31/25 - - Quick Ratio 06/30/26 - - 03/31/26 - - 12/31/25 - - Operating Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Net Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Pre-Tax Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Book Value 06/30/26 - - 03/31/26 - - 12/31/25 - - Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Capital 06/30/26 - - 03/31/26 - - 12/31/25 - -

Powered by Zacks Investment Research ©